PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2014 | 27 | 1 | 10-13
Tytuł artykułu

Review on analgesic effect of co-administrated ibuprofen and caffeine

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Pain is a symptom of many diseases and significantly affects the quality of life, so researchers are constantly seeking new substances to be used as analgesics. Other, easier way is to combine already known drugs which cause synergistic effects greater than additive, so that probability of drug-specific side effects can be reduced. Researchers showed that caffeine can be an effective analgesic adjuvant enhancing antinociceptive effect of ibuprofen in animals and humans. By using modern drug technology methods tablets containing well-soluble ibuprofen salt and caffeine can be easily prepared. Thanks to that combination, the therapeutic dose of ibuprofen can be lowered and the side effects may be reduced.
Słowa kluczowe
Wydawca

Rocznik
Tom
27
Numer
1
Strony
10-13
Opis fizyczny
Daty
wydano
2014-06-01
otrzymano
2013-12-06
zaakceptowano
2014-02-14
online
2014-05-30
Twórcy
  • Department of Applied Pharmacy, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland, andrzej.polski@umlub.pl
  • Department of Applied Pharmacy, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland
  • Department of Organic Chemistry, Medical University of Lublin, Poland
autor
  • Department of Applied Pharmacy, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland
Bibliografia
  • 1. Addams S.S.: The propionic acids: a personal perspective. J. Clin.Pharmacol., 32 (4), 317-323, 1992.[Crossref]
  • 2. Apstein C.S., Vogel W.M.: Coronary arterial vasodilator effect of ibuprofen. J. Pharmacol. Exp. Ther., 220 (1), 167-171, 1982.
  • 3. Barone J.J., Roberts H.R.: Caffeine consumption. Food Chem.Toxicol., 34, 119-129, 1996.
  • 4. Beaver W.T.: Caffeine revisited. JAMA, 251, 1732-1733, 1984.
  • 5. Bishop D.: Dietary supplements and team-sport performance. Sports Med., 40 (12), 995-1017, 2010.[WoS][Crossref]
  • 6. Chin J.M. et al.: Caffeine content of brewed teas. J. Anal. Toxicol., 32 (8), 702-704, 2008.[Crossref]
  • 7. Collins S.L. et al.: Oral ibuprofen and diclofenac in post-operative pain: a quantitative systemic review. J. Pain, 2, 285-291, 1998.
  • 8. Conger S.A. et al.: Does caffeine added to carbohydrate provide additional ergogenic benefit for endurance? Int. J. Sport Nutr. Exerc.Metab., 21 (1), 71-84, 2011.[Crossref][WoS]
  • 9. Curhan S.G. et al.: Analgesic use and the risk of hearing loss in men.Am. J. Med., 123 (3), 231-237, 2010.[WoS][Crossref]
  • 10. Danckwerts M.P., Watt J.G., Moodley I.: The effect of processing variables on the release of ibuprofen and caffeine from controlledrelease nonswellable core-in-cup compressed tablets. Drug Dev. Ind.Pharm., 22 (7), 681-687, 1996.[Crossref]
  • 11. Derry C.J., Derry S., Moore R.A.: Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Rev., 3, 2012.
  • 12. Diamond S., Balm T.K., Freitag F.G.: Ibuprofen plus caffeine in the treatment of tension-type headache. Clin. Pharmacol. Ther., 68, 312-319, 2000.
  • 13. Dooley J.M. et al.: Caffeine as adjuvant to ibuprofen in treating childhood headaches. Pediatr. Neurol., 37 (1), 42-46, 2007.[WoS][Crossref]
  • 14. Fisone G., Borgkvist A., Usiello A.: Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol. Life Sci., 61 (7-8), 857-872, 2004.[Crossref]
  • 15. Forbes J.A. et al.: Evacuation of aspirin, caffeine and their combination in postoperative oral surgery pain. Pharmacotherapy, 10, 387-393, 1990.
  • 16. Fredholm B.B. et al.: Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol.Rev., 51 (1), 83-133, 1999.
  • 17. Granados-Soto V., Castaneda-Hernandez G.: A review of the pharmacokinetic and pharmacodynamic factors in the potentiation of the antinociceptive effect of nonsteroidal anti-infammatory drugs by caffeine. J. Pharm. Toxicol., 42 (2), 67-72, 1999.[Crossref]
  • 18. Holtzman S.G., Mante S., Minneman K.P.: Role of adenosine receptors in caffeine tolerance. J. Pharmacol. Exp. Ther., 256 (1), 62-68, 1990.
  • 19. Kayrak D., Akman U., Hortacsu O.: Micronization of ibuprofen by RESS. J. Supercrit. Fluid., 26, 17-31, 2003.[Crossref]
  • 20. Khoshayand M.R. et al.: Simultaneous spectrophotometric determination of paracetamol, ibuprofen and caffeine in pharmaceuticals by chemometric methods. Spectrochom. Acta A, 70, 491-499, 2008.
  • 21. Koyama R. et al.: Effect of caffeine on ibuprofen-induced gastrin mucosal damage in rats. J. Pharm. Pharmacol., 51, 817-824, 1999.
  • 22. Li J., Zhang Y.: Emerging drug targets for pain treatment. Eur. J.Pharmacol., 681 (1-3), 1-5, 2012.[WoS]
  • 23. Lopez J.R.M. et al.: Enhancement of antinociception by co-administration of ibuprofen and caffeine in arthritic rats. Eur. J.Pharmacol., 544 (1-3), 31-38, 2006.
  • 24. Mao J., Gold M.S., Backonja M.: Combination drug therapy for chronic pain: A call for more clinical studies. J. Pain, 12 (2), 157-166, 2011.[Crossref][WoS]
  • 25. Marczyński Z.: Technologia tabletkowania suchego wyciągu z ziela nawłoci pospolitej (Solidago virgaurea L.) przy użyciu silifikowanej celulozy mikrokrystalicznej (Prosolv) oraz innych wybranych substancji pomocniczych. Polim. Med., 39, 4, 2009.
  • 26. Martindale: The Complete Drug Reference. [online] London: Pharmaceutical Press http://www.medicinescomplete.com (Accessed04.11.2013).
  • 27. McQuay H.J. et al.: Ibuprofen compared with ibuprofen plus caffeine after third molar surgery. Pain, 66 (2-3), 247-251, 1996.[Crossref]
  • 28. More P.K., Khomane K.S., Bansal A.K.: Flow and compaction behavior of ultrafine coated ibuprofen. Int. J. Pharm., 441, 527-534, 2013.
  • 29. Mumford G.K., Neill D.B., Holtzman S.G.: Caffeine elevates reinforcement threshold for electrical brain stimulation: tolerance and withdrawal changes. Brain Res., 459, 163-167, 1988.
  • 30. Ortega-Alvaro A. et al.: Comparison of the antinociceptive effects of ibuprofen arginate and ibuprofen in rat models of inflammatory and neuropathic pain. Life Sci., 90, 13-20, 2012.[WoS]
  • 31. Rao P., Knaus E.E.: Evolution of nonsteroidal ant-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.J. Pharm. Sci., 11 (2), 81-110, 2008.
  • 32. Ritschel W.A., Kearns G.L. (2009). Handbook of basic pharmacokinetics including clinical applications. In: Appendix pharmacokinetics parameters of important drugs. Washington D.C.: APhA; p. 440.
  • 33. Sawynok J., Yaksh T.L.: Caffeine as an analgesic adjuvant: a review of pharmacology and mechanisms of action. Pharmacol. Rev., 45, 43-85, 1993.
  • 34. Sawynok J.: Adenosine receptor activation and nociception. Eur. J.Pharmacol., 317, 1-11, 1998.
  • 35. Sillanpaa M., Piekkala P.: Prevalence of migraine and other headaches in early puberty. Scand. J. Prim. Health Care, 2, 27-32, 1984.[Crossref]
  • 36. Tarnopolsky M.A.: Caffeine and creatine use in sport. Ann. Nutr.Metab., 57 (2), 1-8, 2010.[Crossref][WoS]
  • 37. Tavares C., Sakata R.K.: Caffeine in the treatment of pain. Rev. Bras.Anestesiol., 62 (3), 387-401, 2012.[Crossref]
  • 38. Wee B., Hillier R.: Pain control. Med., 39 (11), 639-644, 2011.[Crossref]
  • 39. World Health Organization. (1996). Cancer pain relief. Geneva, WHO.
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_cipms-2014-0003
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.